| 000 | 01812 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515035216.0 | ||
| 264 | 0 | _c20070719 | |
| 008 | 200707s 0 0 eng d | ||
| 022 | _a0167-6806 | ||
| 024 | 7 |
_a10.1007/s10549-006-9307-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMarcom, P Kelly | |
| 245 | 0 | 0 |
_aThe combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. _h[electronic resource] |
| 260 |
_bBreast cancer research and treatment _cMar 2007 |
||
| 300 |
_a43-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xchemistry |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aIn Situ Hybridization, Fluorescence |
| 650 | 0 | 4 | _aLetrozole |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNitriles _xadministration & dosage |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xanalysis |
| 650 | 0 | 4 |
_aReceptors, Estrogen _xanalysis |
| 650 | 0 | 4 | _aTrastuzumab |
| 650 | 0 | 4 |
_aTriazoles _xadministration & dosage |
| 700 | 1 | _aIsaacs, Claudine | |
| 700 | 1 | _aHarris, Lyndsay | |
| 700 | 1 | _aWong, Zee Wang | |
| 700 | 1 | _aKommarreddy, Aruna | |
| 700 | 1 | _aNovielli, Nellie | |
| 700 | 1 | _aMann, Gretchen | |
| 700 | 1 | _aTao, Yu | |
| 700 | 1 | _aEllis, Matthew J | |
| 773 | 0 |
_tBreast cancer research and treatment _gvol. 102 _gno. 1 _gp. 43-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10549-006-9307-8 _zAvailable from publisher's website |
| 999 |
_c16485308 _d16485308 |
||